EMORY UNIVERSITY NON PROFIT CORP

Their core work

Emory University is a major US research university based in Atlanta, Georgia, contributing specialized biomedical and public health expertise to European research consortia. Their H2020 involvement centers on environmental health — particularly the exposome (how environmental exposures affect human disease) — and infectious disease research including HIV and Ebola vaccine safety. They also bring capacity in tobacco control policy, cancer microenvironment biology, and advanced analytical methods like metabolomics and mass spectrometry to European-led projects.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), Emory's involvement was diverse and exploratory — spanning Ebola vaccine safety, neurological exposome research, pure mathematics (hypergraph theory), and glioblastoma biology. From 2020 onward, their focus sharpened dramatically toward environmental exposure science and its health consequences, with three concurrent projects on urban exposome, microplastics risk, and gut microbiome-immune interactions. This convergence signals a deliberate institutional commitment to understanding how environmental and microbial exposures drive chronic disease.

Emory is consolidating around exposome science, environmental toxicology, and microbiome-immune interactions — expect them to seek partnerships in large-scale environmental health and early-life exposure studies.

How they like to work

Emory never coordinates H2020 projects — all 9 participations are as partner (5 as third party, 4 as participant), reflecting their role as a non-EU institution contributing specialized expertise to European-led consortia. With 81 unique consortium partners across 21 countries, they integrate into large, diverse research networks rather than building their own. Their consistent third-party status in MSCA actions suggests they are frequently sought out for specific methodological or domain knowledge that European teams lack in-house.

Emory has collaborated with 81 distinct partners across 21 countries, giving them one of the broader international networks for a non-EU institution. Their connections span Western and Eastern Europe, reflecting participation in large RIA and MSCA consortia rather than bilateral arrangements.

What sets them apart

As a top-tier US university embedded in European health research consortia, Emory offers something rare: deep American public health and biomedical expertise (Rollins School of Public Health is consistently top-ranked) combined with proven ability to work within EU funding structures. For consortium builders, they represent a credible transatlantic bridge — bringing US-scale cohort data, advanced metabolomics infrastructure, and infectious disease expertise that strengthens any bid targeting global health challenges.

Highlights from their portfolio

• AURORA
  Largest single EC contribution (EUR 842,614), addressing the urgent and growing concern of micro- and nanoplastics impact on early-life health through 2026.
• MISTRAL
  Significant funding (EUR 692,489) combining gut microbiome research with HIV-1 risk stratification — a distinctive intersection of immunology and microbiology.
• EXPANSE
  Part of a major urban exposome initiative connecting environmental exposure data with cardiometabolic and pulmonary health outcomes across European cities.